JAZZ — Jazz Pharmaceuticals plc Common Stock (Ireland) price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $240.71
- YTD price return
- +41.59%
- YTD total return
- +41.59%
- Market cap
- 15.5B
- Enterprise value
- 18.2B
- Shares outstanding
- 64.2M
- 52W low
- $156.95
- 52W high
- $266.38
- From 52W high
- -9.64%
- From 52W low
- +53.37%
- 52W range
- 77%$157–$266
- Beta
- 0.36
Volume
- Rel volume
- 0.62×
- 30D volume
- 807K
- 30D $ vol
- 178.9M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$18.1M
- Insider net 3M
- −$41.4M
- Insider net 1Y
- −$65.9M
Form 4 transactions by trade date, as filed; latest on file 2026-11-06.
Fundamentals
- Sales (ttm)
- 4.7B
- Sales/share
- $73.50
- EPS (ttm)
- $3.15
- FCF (ttm)
- 1.6B
- FCF/share
- $25.26
- Book value/share
- $65.30
- Net margin
- 4.37%
- ROE
- 4.91%
- ROA
- 1.72%
- Debt / equity
- 1.09×
- Current ratio
- 1.82
Growth (CAGR, ttm) · 10Y
- Sales
- +13.49%+7.53%+10.51%+12.66%
- Net income
- n/a+37.07%n/a-5.51%
- FCF
- +21.35%+9.26%+16.21%+12.02%
- Shares
- +5.64%+0.65%+0.87%+0.70%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- n/a+40.06%n/a-5.96%
- Sales/share
- +7.43%+6.84%+9.56%+11.89%
- FCF/share
- +14.87%+8.55%+15.21%+11.24%
- Book value/share
- +0.23%+5.62%+0.38%+8.59%
- Price
- +41.55%+25.91%+12.58%+7.99%
- Total return
- +41.55%+25.91%+12.58%+7.99%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 76.3×
- P/OI (ttm)
- 36.3×
- Fwd P/E
- 9.3×
- P/S (ttm)
- 3.3×
- P/B (mrq)
- 3.7×
- P/FCF (ttm)
- 9.5×
- EV/EBITDA (fy)
- 15.9×
- EV/Sales (ttm)
- 3.9×
- FCF yield (ttm)
- 10.50%
- Buyback yield (realized, 1y)
- -5.64%
- Shareholder yield (realized, 1y)
- -5.64%
- Buyback yield (cash, ttm)
- 1.46%
- Shareholder yield (cash, ttm)
- 1.46%
Vs own 10Y history
- P/E
- 89th
- P/OI
- 82nd
- P/S
- 55th
- P/B
- 90th
- P/FCF
- 48th
Bar = where today’s multiple sits in JAZZ’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m10Y n/mYoY n/mFree cash flow
5Y CAGR +8.0%10Y CAGR +10.1%YoY +6.6%TTM: operating cash flow $1.7B, capex −$70.8M
Q3 2026: operating cash flow $506.1M, capex −$16.2M
Shares (diluted)
5Y +7.9%10Y −3.3%YoY +5.0%Net income
5Y n/m10Y n/mYoY n/mAbout Jazz Pharmaceuticals#
Data provided bySource: Twelve DataJazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.
Dublin, Ireland·2,890 employees·Biotechnology·jazzpharma.com·As of Oct 28, 2026
Recent filings#
- Nov 6Insider sale · COZADD BRUCE C (Director) sold 68,808 shares for $16.2M at $234.91–$237.39
- Nov 4Insider sale · Carr Patricia (SVP, Chief Accounting Officer) sold 1,413 shares for $327K at $231.27–$231.37
- Nov 2Earnings · Earnings release — EPS −$4.83 vs −$5.18 est. (+6.8%); revenue $1.24B (+10% y/y) 7.1%
- Oct 268-K · Results of operations
- Sep 158-K · Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
ETFs holding JAZZ#
20 of the 193 ETFs ChartRow carries live hold JAZZ. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IJH | iShares Core S&P Mid-Cap ETF | 0.4% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.4% |
| VBR | Vanguard Small-Cap Value ETF | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.2% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
